| Literature DB >> 31818817 |
Michael S Sonnabend1,2, Kristina Klein1, Sina Beier3, Angel Angelov1,2, Robert Kluj4, Christoph Mayer4, Caspar Groß5, Kathrin Hofmeister1, Antonia Beuttner1, Matthias Willmann1,2, Silke Peter1,2, Philipp Oberhettinger1, Annika Schmidt1, Ingo B Autenrieth1,2, Monika Schütz1, Erwin Bohn6.
Abstract
With the aim to identify potential new targets to restore antimicrobial susceptibility of multidrug-resistant (MDR) Pseudomonas aeruginosa isolates, we generated a high-density transposon (Tn) insertion mutant library in an MDR P. aeruginosa bloodstream isolate (isolate ID40). The depletion of Tn insertion mutants upon exposure to cefepime or meropenem was measured in order to determine the common resistome for these clinically important antipseudomonal β-lactam antibiotics. The approach was validated by clean deletions of genes involved in peptidoglycan synthesis/recycling, such as the genes for the lytic transglycosylase MltG, the murein (Mur) endopeptidase MepM1, the MurNAc/GlcNAc kinase AmgK, and the uncharacterized protein YgfB, all of which were identified in our screen as playing a decisive role in survival after treatment with cefepime or meropenem. We found that the antibiotic resistance of P. aeruginosa can be overcome by targeting usually nonessential genes that turn essential in the presence of therapeutic concentrations of antibiotics. For all validated genes, we demonstrated that their deletion leads to the reduction of ampC expression, resulting in a significant decrease in β-lactamase activity, and consequently, these mutants partly or completely lost resistance against cephalosporins, carbapenems, and acylaminopenicillins. In summary, the determined resistome may comprise promising targets for the development of drugs that may be used to restore sensitivity to existing antibiotics, specifically in MDR strains of P. aeruginosa.Entities:
Keywords: AmpC β-lactamase; Pseudomonas aeruginosa; TraDIS; antibiotics; clinical isolate; multidrug resistance; peptidoglycan; peptidoglycan recycling
Mesh:
Substances:
Year: 2020 PMID: 31818817 PMCID: PMC7038268 DOI: 10.1128/AAC.01771-19
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191
FIG 1Resistome of the MDR strain ID40 determined by TraDIS. The bacteria comprising the ID40 Tn library were grown in LB with or without 2 μg/ml MEM (A) or 8 μg/ml FEP (B) in 3 independent experiments, and then the DNA of the surviving bacteria was used for sequencing of the Tn-genome junctions. The fold change in expression and adjusted P value for samples grown in antibiotics in comparison to those for samples grown in LB were calculated with DESeq2 software for all annotated genes. All genes with read counts significantly different (adjusted P value, <0.05) from those for the LB control are colored in red.
Meropenem and cefepime resistome in P. aeruginosa ID40
| Category | Identifier | Gene | Name/function | MEM vs LB | FEP vs LB | Orthologue(s) | ||
|---|---|---|---|---|---|---|---|---|
| Ratio | Ratio | |||||||
| Genes with an adjusted | ||||||||
| Resistance | TUEID40_04486 | β-Lactamase | 0.07 | 0.00052 | 0.05 | 3.87E−5 | PA14_10790, PA4110 | |
| PG synthesis/recycling | TUEID40_05675 | Soluble lytic transglycosylase | 0.02 | 5.08E−12 | 0.03 | 3.61E−10 | PA14_25000, PA3020 | |
| TUEID40_05736 | Endolytic murein transglycosylase | 0.02 | 1.32E−33 | 0.03 | 1.77E−41 | PA14_25730, PA2963 | ||
| TUEID40_04290 | Murein | 0.05 | 1.01E−07 | 0.07 | 2.29E−06 | PA14_08540, PA0667 | ||
| TUEID40_02325 | Synthesis of septal peptidoglycan during cell division | 0.11 | 2.76E−05 | 0.20 | 0.0019 | PA14_57360, PA4413 | ||
| TUEID40_02305 | Permease | 0.02 | 7.00E−24 | 0.03 | 1.01E−22 | PA14_57100, PA4393 | ||
| TUEID40_05690 | β- | 0.07 | 1.56E−05 | 0.04 | 6.23E−06 | PA14_25195, PA3005 | ||
| TUEID40_04289 | Anhydro- | 0.12 | 4.938E−10 | 0.20 | 1.62E−06 | PA14_08520, PA0666 | ||
| TUEID40_04233 | 0.08 | 3.05E−06 | 0.17 | 0.0085 | PA14_07780, PA0596 | |||
| TUEID40_04234 | Similar to | 0.07 | 5.10E−05 | 0.15 | 0.0001 | PA14_07790, PA0597 | ||
| LPS | TUEID40_05537 | UDP-2-acetamido-2-deoxy-3-oxo- | 0.10 | 1.58E−03 | 0.135 | 6.43E−03 | PA3155 | |
| Unknown | TUEID40_03245 | YgfB-like proteins, unknown | 0.06 | 2.35E−19 | 0.06 | 5.56E−20 | PA14_69010, PA5225 | |
| TUEID40_05543 | Glycosyltransferase family 1 | 0.02 | 1.35E−09 | 0.02 | 7.79E−10 | |||
| Genes with an adjusted | ||||||||
| PG synthesis/recycling | TUEID40_04881 | Murein | 0.14 | 3.60E−12 | 0.37 | 0.002 | PA14_15100, PA3787 | |
| Type IV pili assembly | TUEID40_03621 | Type IV pilus secretin-associated protein; anchors the outer membrane type IV pili secretin complex to the peptidoglycan | 0.02 | 1.02E−28 | 0.31 | 3.61E−10 | PA14_00210, PA0020 | |
| β-Barrel assembly | TUEID40_01638 | β-Barrel assembly enhancing protease | 0.12 | 2.17E−07 | 0.24 | 1.20E−06 | PA14_51320, PA1005 | |
| Unknown | TUEID40_03216 | Putative zinc protease | 0.14 | 6.06E−05 | 0.21 | 0.001 | PA14_68640, PA5196 | |
| TUEID40_05674 | Uncharacterized conserved protein YecT, DUF1311 family | 0.19 | 9.84E−05 | 0.74 | 1.0 | PA14_24990, PA3021 | ||
| Genes with an adjusted | ||||||||
| PG synthesis/recycling | TUEID40_05519 | 0.27 | 0.14 | 0.185 | 4.12E−02 | PA14_23210, PA3172 | ||
| TUEID40_03006 | Penicillin-binding protein 1 | 0.73 | 0.40 | 0.05 | 3.15E−12 | PA14_66670, PA5045 | ||
| TUEID40_02335 | Penicillin-binding protein activator | 1.03 | 1 | 0.20 | 6.87E−16 | PA14_57480, PA4423 | ||
| Cell division | TUEID40_03247 | Cell division protein ZapA | 0.39 | 0.00017 | 0.17 | 1.00E−07 | PA14_69030, PA5227 | |
| Porin | TUEID40_00776 | Outer membrane protein F | 0,22 | 0.036 | 0.20 | 0.03 | PA14_41570, PA1777 | |
| Unknown | TUEID40_01298 | Uncharacterized putative membrane-bound pyrroloquinoline quinone-dependent dehydrogenase | 0.45 | 0.0018 | 0.16 | 1.80E−08 | PA14_47350, PA1305 | |
Data are for genes for which insertion sequence abundance was significantly reduced (>5-fold; adjusted P value, <0.05) upon exposure to 2 μg/ml MEM or 8 μg/ml FEP. Differences in insertion sequence abundance are expressed as the mean of the ratio of the normalized sequence read numbers of antibiotic-treated culture in relation to the normalized sequence read numbers of the LB control culture of the Tn library. In total, three independent experiments were performed.
Susceptibility of ID40 WT and deletion mutants to β-lactam antibiotics
| Antibiotic | MIC (mg/liter) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Breakpoint | ID40 WT | Δ | Δ | Δ | Δ | Δ | Δ | Δ | PA14 | ||
| Susceptible | Resistant | ||||||||||
| MEM | 2 | 8 | 8 | 8 | 8 | 8 | <0.125 | ||||
| IMP | 4 | 4 | 32 | 32 | 32 | 32 | 32 | <1 | |||
| FEP | 8 | 8 | 16 | 16 | <1 | ||||||
| CAZ | 8 | 8 | 32 | 32 | 32 | 32 | <1 | ||||
| PIP | 16 | 16 | 128 | < | 128 | 128 | <4 | ||||
| TZP | 16 | 16 | 128 | 128 | 128 | 4 | |||||
| ATM | 16 | 16 | 32 | 32 | 8 | ||||||
| FOS | 96 | 96 | 96 | 96 | 96 | 48 | |||||
MICs of ID40 WT and deletion mutant strains were determined by broth microdilution or by Etest for fosfomycin. Susceptible was an MIC less than or equal to the breakpoint, and resistance was an MIC greater than the breakpoint. MIC values for the deletion mutants lower than the MIC for the ID40 WT are in bold, and MICs below the MIC breakpoint are in bold and underlined. MIC values higher than the MIC for the ID40 WT are in italics. MEM, meropenem; IMP, imipenem; FEP, cefepime; CAZ, ceftazidime; PIP, piperacillin; TZP, piperacillin-tazobactam; ATM, aztreonam; FOS, fosfomycin.
FIG 2β-Lactamase activity and ampC expression in selected deletion mutants. WT and deletion mutant strains were subcultured, and β-lactamase activity was measured by a nitrocefin turnover assay (A) or expression of the ampC β-lactamase gene was determined by qRT-PCR (B) in at least 3 independent experiments. Graphs depict the means and SDs. Student's t test was performed for determination of the difference in the results for each mutant strain in comparison to those for the WT. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
FIG 3Simplified scheme of PG recycling and synthesis pathway of P. aeruginosa and illustration of the proteins identified by TraDIS. The bacterial murein matrix is formed by chains of the two alternating amino sugars MurNAc (M) and GlcNAc (G), which are linked by β(1→4) glycosidic bonds. Attached to the MurNAc residues is a pentapeptide side chain which typically is composed of l-alanine–γ-d-glutamate–meso-diaminopimelic acid–d-alanyl-d-alanine (l-Ala–γ-d-Glu–m-DAP–d-Ala-d-Ala). Cross-links between adjacent glycans are mainly built by connecting the meso-diaminopimelic acid of one chain with the d-Ala of the other chain. PG synthesis starts in the cytoplasm, where fructose-6-phosphate is converted in several steps by GlmS, GlmM, and GlmU to UDP-GlcNAc. UDP-GlcNAc is further converted to UDP-MurNAc by Mur enzymes A and B, and subsequently, a peptide chain is added by Mur ligases C, D, E, and F to form UDP-MurNAc-pentapeptide. An alternative route to generate UDP-MurNAc-pentapeptide starts with the transfer of GlcNAc-1,6-anhMurNAc-peptides (muropeptides) along with GlcNAc-anhMurNAc into the cytoplasm by the permease AmpG. Some muropeptides (however, not GlcNAc-1,6-anhMurNAc-peptides) or free peptides may also be transported through AmpP, but its function in cell wall recycling has not been elucidated so far. The imported muropeptides are subsequently degraded by NagZ, l,d-carboxypeptidase LdcA, and AmpD, producing d-Ala, GlcNAc, l-Ala–iso-d-glutamate–meso-diaminopimelic acid tripeptide, and 1,6-anhMurNAc. AnmK then catalyzes the phosphorylation of 1,6-anhMurNAc, generating MurNAc-6P, which is further processed by MupP and the sugar kinase AmgK to MurNAc-α-1P. The uridylyltransferase MurU then converts the latter to UDP-MurNAc, following the formation of UDP-MurNAc-pentapeptide. The phospho-MurNAc-pentapeptide moiety is then transferred by the cytosolic translocase MraY to the lipid carrier undecaprenol phosphate (Und-P) to generate lipid I, which is subsequently catalyzed by MurG to lipid II by adding GlcNAc to it. Lipid II is then flipped into the periplasm (likely by the putative flippase MurJ), where GlcNAc-MurNAc-peptides are integrated into the growing PG by high-molecular-mass penicillin-binding proteins; glycosyltransferases (GTFs), such as FtsW and RodA; transpeptidases (TPs); and dd-carboxypeptidases (CPs). Low-molecular-mass penicillin-binding proteins, endopeptidases (EPs; such as MepM1), lytic transglycosylases (such as MltG and Slt), and amidases (such as AmpDh2 and AmpDh3) finally cleave the existing PG layer to facilitate the insertion of new glycan strands and simultaneously to release the PG degradation products from the matrix into the cytoplasm. Under normal conditions, the PG precursor UDP-MurNAc-pentapeptide binds to AmpR, causing the repression of ampC transcription. In the case of β-lactam treatment, the turnover of the muropeptides is increased (by blockage of PG cross-links), resulting in the accumulation of 1,6-anhMurNAc-pentapeptide in the cytoplasm. The 1,6-anhMurNAc-muropeptides are able to displace UDP-MurNAc-pentapeptides from AmpR, causing the derepression and, hence, activation of ampC transcription. YgfB also modulates ampC expression, contributing finally to β-lactam resistance, but its specific role in mediating antibiotic resistance remains to be investigated. The proteins found via TraDIS are highlighted with a circle in red for proteins mediating repression of ampC expression and with a circle in green for proteins mediating derepression of ampC expression. The putative FtsW protein (so far not verified in P. aeruginosa) and the unknown mechanism of YgfB are labeled with interrupted lines. OM, outer membrane; P, periplasm; IM, inner membrane; C, cytoplasm; PG, peptidoglycan; CPs, dd-carboxypeptidases; GTFs, glycosyltransferases; EPs, endopeptidases; LTs, lytic transglycosylases; *, AmgK, MupP, and MurU cell wall recycling enzymes found in P. aeruginosa but not in enterobacteria, such as E. coli (38, 40, 41).